The Era of Immunotherapy in Small-Cell Lung Cancer: More Shadows Than Light?
Sabrina Rossi, Arianna Pagliaro, Angelica Michelini, Pierina Navarria, Elena Clerici, Davide Franceschini, Luca Toschi, Giovanna Finocchiaro, Marta Scorsetti, Armando Santoro, Massimo Broggini, Myung-Ju Ahn · 2023
Read The Era of Immunotherapy in Small-Cell Lung Cancer: More Shadows Than Light? by Sabrina Rossi, Arianna Pagliaro, Angelica Michelini, Pierina Navarria, Elena Clerici, Davide Franceschini, Luca Toschi, Giovanna Finocchiaro, Marta Scorsetti, Armando Santoro, Massimo Broggini, Myung-Ju Ahn (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10741846.txt.
Description
Sabrina Rossi and co-authors reviewed immunotherapy for small-cell lung cancer in two thousand twenty-three. The disease responds well to chemotherapy at first, and adding immunotherapy gave a small survival gain in key trials. Many questions remain, including where radiotherapy fits.
Two common markers, PD-L1 and tumor mutation burden, have not proven reliable for picking responders, the authors find. A newer split of the disease by key transcription factors may explain behavior better, but clinical use is still far off. The review weighs patient traits and possible biomarkers that could identify who benefits most. The authors call the era mixed, with more shadows than light so far.
Catalog record
| CREATOR | Sabrina Rossi, Arianna Pagliaro, Angelica Michelini, Pierina Navarria, Elena Clerici, Davide Franceschini, Luca Toschi, Giovanna Finocchiaro, Marta Scorsetti, Armando Santoro, Massimo Broggini, Myung-Ju Ahn |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |